The CDTI Innovation invests, together with BIO & TECH SMART CAPITAL FCRE, ONCOSTELLAE S.L., who develops medicines for treatment of diseases with unmet medical needs
The CDTI innovation, through its programme Innvierte, together with BIO & TECH SMART FCRE CAPITAL, has reached an agreement with the partners of ONCOSTELLAE, S.L., to enter the capital of the company.
Oncostellae is a spanish biopharmaceutical focused on the discovery and development of new drugs with a solid intellectual property and global rights aimed at indications in oncology иммунология with great care not covered.
The company was founded in 2013 by a team of doctors and chemical farmacólogos aimed at developing clinical candidates from conception until the early stages in the clinic and licensing human development and marketing post-consolidated pharmaceutical companies.
Julio Castro (founder), Guido Kurz (CEO) and Cristina Balagué (CSO)
The most advanced Oncostellae is addressed to the treatment of inflammatory intestinal diseases (EII). The candidate to drug, OST-122, was a novel quinasas of Janus (JAK) acting exclusively in the gastrointestinal tract and avoids inherent systemic toxicidades in protease present JAK. OST-122 has just successfully completing a proof of concept (clinical trial phase 2a) in patients with ulcerative colitis demonstrating an excellent safety profile and effectiveness. A second candidate, drug OST-499 - a receiver no-esteroidal glucocorticoide (GR) and activator of the immune system - is currently in a phase 1 in patients with solid tumors. A third programme around kinase inhibitor ARK5, OST-664, is addressed to the treatment of fibrosis and is in the process of preclinical.
The investment of Bio & Tech Smart Capital and CDTI Innovation will serve to continue the development of and OST-664 OST-499 and engage in business development for licensing OST-122.
BIO & TECH SMART FCRE CAPITAL
Bio & Tech Smart FCRE Capital, is the first investment fund galician specializing in key sectors such as technological biotechnology, medicine, health, diagnosis and digital technology applied to the life sciences.
Our team is composed of professionals with extensive experience in Venture Capital, as well as researchers and entrepreneurs with a profound knowledge of the sector. This combination allows us to identify projects with innovative technologies and high growth potential, to accelerate it through our experience in investment and entrepreneurship, supported by an extensive network of contacts with access to national and international markets.
Galicia boasts a sound ecosystem in biotechnology endorsed by the university research and institutional support, which provide us access to quality startups with great capacity for development.
Bio & Tech Smart Capital aims to promote the creation of business fabric in the region, to support entrepreneurs at an early stage to projects series A, with a focus on continuous monitoring to ensure the success, to provide investors with an opportunity to obtain attractive returns.
With a hard cap 30 million euros, we have planned to invest in 15-25 projects, with the commitment that half of these investments are aimed at startups based in Galicia.
CDTI Innovation
The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology. The CDTI also supports the creation and consolidation of technology-based enterprises in Spain.
The centre for technological development and innovation, E.P.E. (CDTI) is a public entity under the ministry of Science, innovation and universities.
Further information,:
Office of the press
prensa@cdti.es
91-581.55.00
On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial
This content is copyright © 2024 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).